THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Dr. Emil Kakkis at the Rare Entrepreneur Bootcamp Imagine you or someone you love is diagnosed with a rare disease and then told, “There is no cure, there are no treatments and because it’s so rare no one is even doing any research into developing a … Continue reading The bootcamp helping in the fight against rare diseases
clinical trials
Stem cell agency invests in therapy using killer cells to target colorectal, breast and ovarian cancers
While there have been some encouraging advances in treating cancer in recent decades, there are still many cancers that either resist treatment or recur after treatment. Today the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing in a therapy targeting some of these hard-to-treat tumors. BioEclipse Therapeutics Inc. was awarded nearly … Continue reading Stem cell agency invests in therapy using killer cells to target colorectal, breast and ovarian cancers
Expanding CIRM’s Alpha Clinics Network to deliver transformative regenerative medicine treatmentsÂ
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Almost every day, we hear new reports from the thousands of regenerative medicine clinical trials globally sponsored by hundreds of companies and academic researchers. The California Institute for Regenerative Medicine (CIRM) is a leader in this space supporting some of the most advanced cell and gene … Continue reading Expanding CIRM’s Alpha Clinics Network to deliver transformative regenerative medicine treatmentsÂ
Reversing hearing loss through regenerative medicine
These images show cellular regeneration, in pink, in a preclinical model of sensorineural hearing loss. The control is on the left and the right has been treated. Image: Hinton AS, Yang-Hood A, Schrader AD, Loose C, Ohlemiller KK, McLean WJ. Most of us know someone affected by hearing loss, but we may not fully realize … Continue reading Reversing hearing loss through regenerative medicine
Stem cell-derived retinal patch continues to show promising results two years post-implantation
Earlier this year we wrote about the promising results of a phase 1 clinical trial aimed at replacing the deteriorating cells in the retinas of people suffering from age-related macular degeneration- one of the leading causes of blindness worldwide for people over 50. Now there’s even more good news! Highlighted in a news story on … Continue reading Stem cell-derived retinal patch continues to show promising results two years post-implantation
CIRM-Funded Study of Deadly Immune Disorder Gets Boost from FDA
Hataalii Begay, age 4, first child treated with UCSF gene therapy for Artemis-SCID When Hataalii Begay was born in a remote part of the Navajo nation he was diagnosed with a rare, usually fatal condition, Artemis-SCID. New stem cell therapy Today, thanks to a therapy developed at UCSF and funded by CIRM, he's a normal healthy … Continue reading CIRM-Funded Study of Deadly Immune Disorder Gets Boost from FDA
First Patient Dosed in Phase 1 Clinical Trial for T1D
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D
CIRM-funded stem cell clinical trial patients: Where are they now?
Ronnie with his parents Pawash Priyank and Upasana Thakur. Since its launch in 2004, the California Institute for Regenerative Medicine (CIRM) has been a leader in growing the stem cell and regenerative medicine field while keeping the needs of patients at the core of its mission. To date, CIRM has: Advanced stem cell research and therapy development for … Continue reading CIRM-funded stem cell clinical trial patients: Where are they now?
A CIRM-funded therapy for a deadly blood cancer gets approval for Phase 3 clinical trial
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Michael Wang, MD (right) of the Department of Lymphoma & Myeloma at MD Anderson Cancer Center will lead the Phase 3 clinical Oncternal Therapeutics, Inc. is celebrating an encouraging milestone at the start of the new year following a successful End-of-Phase 2 meeting with the FDA. Specifically, the FDA agreed on key … Continue reading A CIRM-funded therapy for a deadly blood cancer gets approval for Phase 3 clinical trial
Lack of diversity leaves cloud hanging over asthma drug study
Asthma spacer, photo courtesy Wiki Media Creative Commons THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST If you want to know if a new drug or therapy is going to work in the people it affects the most you need to test the drug or therapy in the people most affected by the disease. … Continue reading Lack of diversity leaves cloud hanging over asthma drug study